{"id":"cabotegravir-cab-tablet","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Injection site reactions (pain, induration, erythema)"},{"rate":"10-20","effect":"Headache"},{"rate":"5-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"<1","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL2403238","moleculeType":"Small molecule","molecularWeight":"405.36"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabotegravir binds to the active site of HIV integrase and inhibits the strand transfer step of viral integration. By blocking this critical step in the HIV replication cycle, the drug prevents establishment of persistent infection. It is designed for long-acting formulation, allowing extended dosing intervals compared to daily oral antiretrovirals.","oneSentence":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:34.961Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection treatment (in combination antiretroviral therapy)"},{"name":"HIV-1 pre-exposure prophylaxis (PrEP)"}]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT02720094","phase":"PHASE2, PHASE3","title":"Injectable Cabotegravir Compared to TDF/FTC For PrEP in HIV-Uninfected Men and Transgender Women Who Have Sex With Men","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-12-19","conditions":"HIV Infections","enrollment":4570},{"nctId":"NCT07473778","phase":"","title":"Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention","status":"NOT_YET_RECRUITING","sponsor":"Gilead Sciences","startDate":"2026-03","conditions":"HIV Infections","enrollment":3000},{"nctId":"NCT05917509","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2023-07-06","conditions":"HIV Infections","enrollment":171},{"nctId":"NCT05514509","phase":"PHASE4","title":"A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2022-10-28","conditions":"HIV Infections","enrollment":370},{"nctId":"NCT07390409","phase":"","title":"ALIGN: A Non-randomised Study Delivering Injectable Lenacapavir for HIV Prevention Within a Pre-exposure Prophylaxis (PrEP) Choice Context in Cape Town, South Africa.","status":"NOT_YET_RECRUITING","sponsor":"Desmond Tutu HIV Foundation","startDate":"2026-01-29","conditions":"HIV","enrollment":3700},{"nctId":"NCT03497676","phase":"PHASE1, PHASE2","title":"More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-03","conditions":"HIV Infections","enrollment":168},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT03164564","phase":"PHASE3","title":"Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-11-07","conditions":"HIV Infections","enrollment":3224},{"nctId":"NCT03635788","phase":"PHASE3","title":"The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-28","conditions":"HIV Infections","enrollment":456},{"nctId":"NCT03299049","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2017-10-27","conditions":"HIV Infections","enrollment":1049},{"nctId":"NCT05660980","phase":"PHASE1, PHASE2","title":"Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-01-24","conditions":"HIV-1-infection","enrollment":90},{"nctId":"NCT03739996","phase":"PHASE2","title":"Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-31","conditions":"HIV Infections","enrollment":75},{"nctId":"NCT04692077","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Males","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-19","conditions":"HIV Infections","enrollment":9},{"nctId":"NCT04824131","phase":"PHASE2","title":"Safety, Tolerability and Acceptability of Long-Acting Cabotegravir (CAB LA) for the Prevention of HIV Among Adolescent Females","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-11-04","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05546242","phase":"PHASE3","title":"Improving HIV-1 Control in Africa with Long Acting Antiretrovirals","status":"ACTIVE_NOT_RECRUITING","sponsor":"MRC/UVRI and LSHTM Uganda Research Unit","startDate":"2022-12-08","conditions":"HIV-1-infection","enrollment":540},{"nctId":"NCT02120352","phase":"PHASE2","title":"A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-04-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":309},{"nctId":"NCT04542070","phase":"PHASE3","title":"A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-11-09","conditions":"HIV Infections","enrollment":687},{"nctId":"NCT06405464","phase":"","title":"Cabotegravir Plus Rilpivirine Long-acting Regimen in the Swiss HIV Cohort Study:Uptake, Outcome, and Risk Factors for Treatment Failures","status":"RECRUITING","sponsor":"University of Zurich","startDate":"2022-03-01","conditions":"HIV Infections","enrollment":600},{"nctId":"NCT04399551","phase":"PHASE3","title":"A Study Evaluating Implementation Strategies for Cabotegravir (CAB)+ Rilpivirine (RPV) Long-acting (LA) Injectables for Human Immunodeficiency Virus (HIV)-1 Treatment in European Countries","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-09-28","conditions":"HIV Infections","enrollment":437},{"nctId":"NCT06273943","phase":"PHASE3","title":"Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.","status":"NOT_YET_RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2024-04-01","conditions":"Prevention","enrollment":322},{"nctId":"NCT05776108","phase":"PHASE1","title":"A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2023-03-23","conditions":"HIV Infections","enrollment":24},{"nctId":"NCT04484337","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2020-07-31","conditions":"HIV Infections","enrollment":138},{"nctId":"NCT04001803","phase":"PHASE3","title":"Study to Identify and Determine Best Implementation Practices for Injectable Cabotegravir+Rilpivirine in the United States (US)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-07-08","conditions":"HIV Infections","enrollment":115},{"nctId":"NCT03422172","phase":"PHASE1","title":"A Safety, Tolerability, Acceptability, and Pharmacokinetic (PK) Study of Cabotegravir (CAB) in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Chinese Men","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2018-04-10","conditions":"HIV Infections","enrollment":48},{"nctId":"NCT03149848","phase":"PHASE1","title":"Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-06-06","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":15},{"nctId":"NCT02478463","phase":"PHASE1","title":"Pharmacokinetic Study of Cabotegravir Long-acting in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2017-02-27","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":19},{"nctId":"NCT02411435","phase":"PHASE1","title":"Effect of Rifampin (RIF) on the Pharmacokinetics (PK) of Oral Cabotegravir (CAB) in Healthy Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-07","conditions":"Infection, Human Immunodeficiency Virus","enrollment":15},{"nctId":"NCT02345707","phase":"PHASE1","title":"Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2015-03","conditions":"Infection, Human Immunodeficiency Virus","enrollment":37},{"nctId":"NCT02059031","phase":"PHASE1","title":"A Study to Assess The Relative Bioavailability of New Tablet Formulations of GSK1265744 in Healthy Adult Subjects","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-02","conditions":"Infection, Human Immunodeficiency Virus","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CAB"],"phase":"phase_3","status":"active","brandName":"Cabotegravir (CAB) tablet","genericName":"Cabotegravir (CAB) tablet","companyName":"National Institute of Allergy and Infectious Diseases (NIAID)","companyId":"national-institute-of-allergy-and-infectious-diseases-niaid","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabotegravir is an integrase strand transfer inhibitor (INSTI) that blocks HIV integrase, preventing the virus from inserting its genetic material into human host cell DNA. Used for HIV-1 infection treatment (in combination antiretroviral therapy), HIV-1 pre-exposure prophylaxis (PrEP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}